Home/Filings/4/0000950103-16-014334
4//SEC Filing

Anacor Pharmaceuticals, Inc. 4

Accession 0000950103-16-014334

CIK 0001411158operating

Filed

Jun 23, 8:00 PM ET

Accepted

Jun 24, 2:44 PM ET

Size

16.4 KB

Accession

0000950103-16-014334

Insider Transaction Report

Form 4
Period: 2016-06-24
Bell Graeme
Executive VP and CFO
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2016-06-2425,2990 total
    Exercise: $78.91Common Stock (25,299 underlying)
  • Disposition to Issuer

    Performance Restricted Stock Units

    2016-06-248,0080 total
    Common Stock (8,008 underlying)
  • Disposition to Issuer

    Performance Restricted Stock Units

    2016-06-244,0040 total
    Common Stock (4,004 underlying)
  • Disposition to Issuer

    Performance Restricted Stock Units

    2016-06-245,0000 total
    Common Stock (5,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2016-06-2428,7930 total
    Exercise: $69.34Common Stock (28,793 underlying)
  • Disposition to Issuer

    Common Stock

    2016-06-24$99.25/sh10,488$1,040,9340 total
Footnotes (2)
  • [F1]As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units (including performance restricted stock units) and stock options became fully vested and (iii) each award of restricted stock units (including performance restricted stock units) and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price.
  • [F2]Includes shares acquired pursuant to the Issuer's ESPP since the reporting person's last Form 4.

Issuer

Anacor Pharmaceuticals, Inc.

CIK 0001411158

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001411158

Filing Metadata

Form type
4
Filed
Jun 23, 8:00 PM ET
Accepted
Jun 24, 2:44 PM ET
Size
16.4 KB